doi: 10.1161/hc4301.098252
(Circulation. 2001;104:2177.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Bradykinin Contributes to the Vasodilator Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure
From the Department of Cardiovascular Research, University of Edinburgh, Royal Infirmary of Edinburgh and Department of Clinical Pharmacology, Western General Hospital (D.J.W.), Edinburgh, Scotland, UK.
Correspondence to Dr D.E. Newby, Cardiovascular Research, Department of Cardiology, Royal Infirmary, Lauriston Place, Edinburgh EH3 9YW, Scotland, UK. E-mail d.e.newby{at}ed.ac.uk
Background— Bradykinin, an endogenous vasodilator peptide, is metabolized by ACE. The aims of the present study were to determine the doses of B9340, a bradykinin receptor antagonist, that inhibit vasodilatation to exogenous bradykinin and to assess the contribution of bradykinin to the maintenance of basal vascular tone in patients with heart failure receiving chronic ACE inhibitor therapy.
Methods and Results— Forearm blood flow was measured using bilateral venous occlusion plethysmography. On three occasions in a double-blind randomized manner, 8 healthy volunteers received intrabrachial infusions of placebo or B9340 (at 4.5 and 13.5 nmol/min). On each occasion, placebo or B9340 was coinfused with bradykinin (30 to 3000 pmol/min) and substance P (4 to 16 pmol/min). B9340 caused no change in basal FBF but produced dose-dependent inhibition of the vasodilatation to bradykinin (P<0.001) but not substance P. The effects of bradykinin antagonism were studied in 17 patients with NYHA grade II through IV heart failure maintained on chronic ACE inhibitor therapy. Incremental doses of B9340, but not HOE-140, produced a dose-dependent vasoconstriction (P=0.01). After withdrawal of ACE inhibitor therapy, B9340 produced no significant change in forearm blood flow. After reinstitution of therapy, B9340 again resulted in vasoconstriction (P<0.03).
Conclusions— B9340 is a potent and selective inhibitor of bradykinin-induced vasodilatation. Bradykinin does not contribute to the maintenance of basal peripheral arteriolar tone in healthy humans or patients with heart failure but contributes to the vasodilatation associated with chronic ACE inhibitor therapy in patients with heart failure via the B1 receptor.
Key Words: bradykinin • heart failure • blood flow
This article has been cited by other articles:
 |
|
 |
|
  A. M. Marney, J. Ma, J. M. Luther, T. A. Ikizler, and N. J. Brown Endogenous Bradykinin Contributes to Increased Plasminogen Activator Inhibitor 1 Antigen following Hemodialysis J. Am. Soc. Nephrol., October 1, 2009; 20(10): 2246 - 2252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Meune, K. Wahbi, Y. Fulla, A. Cohen-Solal, D. Duboc, I. Mahe, G. Simoneau, J.-F. Bergmann, S. Weber, and S. Mouly Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors Eur J Heart Fail, February 1, 2007; 9(2): 197 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Chen, P. A. Deddish, R. D. Minshall, R. P. Becker, E. G. Erdos, and F. Tan Human ACE and bradykinin B2 receptors form a complex at the plasma membrane FASEB J, November 1, 2006; 20(13): 2261 - 2270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Gudmundsdottir, I. L. Megson, J. S. Kell, C. A. Ludlam, K. A.A. Fox, D. J. Webb, and D. E. Newby Direct Vascular Effects of Protease-Activated Receptor Type 1 Agonism In Vivo in Humans Circulation, October 10, 2006; 114(15): 1625 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Weiler and R. G. Van Dellen Genetic Test Indications and Interpretations in Patients With Hereditary Angioedema Mayo Clin. Proc., July 1, 2006; 81(7): 958 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L.M. Cruden, G. H. Tse, K. A.A. Fox, C. A. Ludlam, I. Megson, and D. E. Newby B1 Kinin Receptor Does Not Contribute to Vascular Tone or Tissue Plasminogen Activator Release in the Peripheral Circulation of Patients With Heart Failure Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 772 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L.M. Cruden, K. A.A. Fox, C. A. Ludlam, N. R. Johnston, and D. E. Newby Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin-Converting Enzyme Inhibition Hypertension, December 1, 2004; 44(6): 913 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray, M. A. Pfeffer, K. Swedberg, and V. J. Dzau Which Inhibitor of the Renin-Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? Circulation, November 16, 2004; 110(20): 3281 - 3288. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ignjatovic, S. Stanisavljevic, V. Brovkovych, R. A. Skidgel, and E. G. Erdos Kinin B1 Receptors Stimulate Nitric Oxide Production in Endothelial Cells: Signaling Pathways Activated by Angiotensin I-Converting Enzyme Inhibitors and Peptide Ligands Mol. Pharmacol., November 1, 2004; 66(5): 1310 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Bascands and J. P. Schanstra Bradykinin and Renal Fibrosis: Have We ACE'd it? J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2504 - 2506. [Full Text] [PDF]
|
|
|
|
|
|
N. L.M. Cruden, F. N. Witherow, D. J. Webb, K. A.A. Fox, and D. E. Newby Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1043 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Unger and Jun Li The role of the renin-angiotensin-aldosterone system in heart failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1_suppl): S7 - S10. [Abstract] [PDF]
|
|
|
|
|
|
K. Swedberg Conclusions on the management of heart failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1_suppl): S34 - S36. [Abstract] [PDF]
|
|
|
|
 |
|
 W S Waring, S H Adwani, O Breukels, D J Webb, and S R J Maxwell Hyperuricaemia does not impair cardiovascular function in healthy adults Heart, February 1, 2004; 90(2): 155 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tonduangu, L. Hittinger, B. Ghaleh, P. Le Corvoisier, L. Sambin, S. Champagne, T. Badoual, F. Vincent, A. Berdeaux, B. Crozatier, et al. Chronic Infusion of Bradykinin Delays the Progression of Heart Failure and Preserves Vascular Endothelium-Mediated Vasodilation in Conscious Dogs Circulation, January 6, 2004; 109(1): 114 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. N. Witherow, P. Dawson, C. A. Ludlam, D. J. Webb, K. A.A. Fox, and D. E. Newby Bradykinin Receptor Antagonism and Endothelial Tissue Plasminogen Activator Release in Humans Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1667 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Jennings New definitions in cardiovascular risk management: is it time for angiotensin II receptor blockers to become first-line medication? Eur. Heart J. Suppl., August 1, 2003; 5(suppl_F): F3 - F11. [Abstract] [PDF]
|
|
|
|
|
|
D. J. Campbell Vasopeptidase Inhibition: A Double-Edged Sword? Hypertension, March 1, 2003; 41(3): 383 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. N. Witherow, P. Dawson, C. A. Ludlam, K. A. A. Fox, and D. E. Newby Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy J. Am. Coll. Cardiol., September 4, 2002; 40(5): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fujii, A. Wada, T. Tsutamoto, M. Ohnishi, T. Isono, and M. Kinoshita Bradykinin Improves Left Ventricular Diastolic Function Under Long-Term Angiotensin-Converting Enzyme Inhibition in Heart Failure Hypertension, May 1, 2002; 39(5): 952 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. McMurray and M. A. Pfeffer New Therapeutic Options in Congestive Heart Failure: Part I Circulation, April 30, 2002; 105(17): 2099 - 2106. [Full Text] [PDF]
|
|